Skip to main content

Topical sirolimus gel for hyperplastic rosacea: A randomized, double-blind, controlled study and exploration of two-dimensional to three-dimensional approximate protrusion volume (APV) assessment

In brief

Topical sirolimus doubled clear-or-nearly-clear responses in hyperplastic rosacea

In a 65-person randomized trial, 72% using sirolimus gel reached clear or nearly clear after 12 weeks, compared with 33% using placebo; redness ratings also improved more with sirolimus. The small, single-center study found no serious adverse events, but short follow-up and an unvalidated volume measure mean larger confirmatory trials are needed.

Journal
Journal of the American Academy of Dermatology (Q1)
Published
10 November 2026
Study design
Randomized controlled trial
Evidence level
Level 1, High (CEBM 1b)
Authors
Bingyang Xu, Hao Chen, Jiali Chu, Yuanqin Wang, Nan Kou, Biao Yu, et al.
PMID
43007256
DOI
10.1016/j.jaad.2026.10.037

Why clinicians should know about it

  • Picked for Dermatology (top studies of the week, 15 November 2026): Placebo-controlled trial of topical sirolimus for hyperplastic rosacea

Abstract

BACKGROUND: Hyperplastic rosacea is difficult to treat. Sirolimus may be a topical option. OBJECTIVE: To evaluate topical sirolimus gel and explore two-dimensional-to-three-dimensional approximate protrusion volume (APV) assessment. METHODS: In this randomized, double-blind, placebo-controlled trial, 65 patients applied 0.2% sirolimus gel (n = 29) or placebo (n = 36) twice daily. The primary endpoint was an Investigator's Global Assessment (IGA) score ≤1 after a 12-week cycle. Secondary and exploratory endpoints included Clinician's Erythema Assessment (CEA) success, artificial intelligence-estimated APV change, subgroup analyses, and correlations between APV and clinical scores. RESULTS: IGA success was 72.4% versus 33.3% (adjusted relative risk, 1.949; 95% confidence interval [CI], 1.153-3.294; P = .013), and CEA success was 69.0% versus 30.6% (adjusted relative risk, 2.778; 95% CI, 1.627-4.743; P < .001). APV reduction was greater with sirolimus (-61.556 units; P < .001). Baseline APV correlated with IGA (ρ = 0.386; P = .001) and CEA (ρ = 0.314; P = .011). No serious adverse events occurred. LIMITATIONS: Single-center design, small sample, short follow-up, unvalidated algorithm, and no systemic absorption, quality-of-life, or satisfaction assessments. CONCLUSION: Topical sirolimus gel showed exploratory clinical and APV signals; confirmatory trials are needed.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.